Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/105235
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Computing-
dc.creatorWei, J-
dc.creatorWu, X-
dc.creatorWang, S-
dc.creatorLiu, S-
dc.creatorGao, X-
dc.date.accessioned2024-04-12T06:50:56Z-
dc.date.available2024-04-12T06:50:56Z-
dc.identifier.urihttp://hdl.handle.net/10397/105235-
dc.language.isoenen_US
dc.publisherFrontiers Research Foundationen_US
dc.rightsCopyright © 2023 Wei, Wu, Wang, Liu and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsThe following publication Wei J, Wu X, Wang S, Liu S and Gao X (2023) Spatial heterogeneity and Immune infiltration of cellular lysosomal pathways reveals a new blueprint for tumor heterogeneity in esophageal cancer. Front. Endocrinol. 14:1138457 is available at https://doi.org/10.3389/fendo.2023.1138457.en_US
dc.subjectCellular autophagyen_US
dc.subjectEsophageal squamous cell carcinomaen_US
dc.subjectImmune infiltrationen_US
dc.subjectLysosomesen_US
dc.subjectSingle-gene sequencingen_US
dc.titleSpatial heterogeneity and immune infiltration of cellular lysosomal pathways reveals a new blueprint for tumor heterogeneity in esophageal canceren_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume14-
dc.identifier.doi10.3389/fendo.2023.1138457-
dcterms.abstractBackground: Esophageal squamous cell carcinoma (ESCC) is a common Malignant tumor of digestive tract which have a potential association with lysosomal pathway. The purpose of this study was to explore the correlation between lysosome pathway and immune infiltration of ESCC.-
dcterms.abstractMethods: The cell type annotation of ESCC patients and the distribution of their gene markers were analyzed by single cell data. They were also grouped according to the expression of lysosomal pathways. Gene set variation analysis (GSVA) enriched pathway scoring, Cellchat cell communication was performed to demonstrate the tumour-associated pathway scores and interactions of different cell populations. Relevant differential genes were screened, prognostic risk markers were constructed and direct associations of lysosomal pathway-related gene risk scores with immune infiltration and tumour treatment drug sensitivity were assessed by algorithms. In cellular experiments, qPCR and flow cytometry were used to assess the role of the lysosomal pathway gene-MT1X on tumour cell development.-
dcterms.abstractResults: ESCC single cell data were annotated into 7 Cluster clusters by t-sne downscaling analysis. Cellchat analysis revealed that the “MIF” cellular communication network is the main communication mode of the lysosomal pathway in ESCC cells. The lysosomal pathway genetic risk model was found to be significantly different from ESCC prognosis in both the training and validation groups. The lysosome pathway gene risk model was associated with treatment resistance in ESCC patients using oncopredict R package. The correlation between the expression of lysosomal-DEG and tumour immune infiltration and immune cell types by the MCPcounter method. Cellular assays showed that the lysosomal pathway gene MT1X was less expressed in oesophageal cancer cells than in normal oesophageal epithelial cells. Knockdown of MT1X significantly promoted the growth rate of oesophageal cancer cells.-
dcterms.abstractConclusion: Based on the single cell sequencing technology and transcriptomic analysis, we confirmed that there is a close association between the lysosomal pathway and the immune infiltration and treatment sensitivity of ESCC, which may be a potential target for a new direction of ESCC therapy.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationFrontiers in Endocrinology, 2023, v. 14, 1138457-
dcterms.isPartOfFrontiers in Endocrinology-
dcterms.issued2023-
dc.identifier.scopus2-s2.0-85153099995-
dc.identifier.eissn1664-2392-
dc.identifier.artn1138457-
dc.description.validate202403 bcvc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceNot mentionen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
fendo-14-1138457.pdf7.8 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

16
Citations as of Jul 7, 2024

Downloads

8
Citations as of Jul 7, 2024

SCOPUSTM   
Citations

1
Citations as of Jul 4, 2024

WEB OF SCIENCETM
Citations

1
Citations as of Jul 4, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.